Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KRYS Krystal Biotech Inc.

休市中 01-09 16:00:00 EST

261.41

+12.50

+5.02%

盘后261.41

+0.000.00%

19:08 EST

最高267.48	最低252.92	成交量34.99万
今开254.51	昨收248.91	日振幅5.85%
总市值75.80亿	流通市值60.07亿	总股本2,900万
成交额9,112万	换手率1.52%	流通股本2,298万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KRYS","market":"US","secType":"STK","nameCN":"Krystal Biotech Inc.","latestPrice":261.41,"timestamp":1767992400000,"preClose":248.91,"halted":0,"volume":349867,"hourTrading":{"tag":"盘后","latestPrice":261.41,"preClose":261.41,"latestTime":"19:08 EST","volume":2855,"amount":746320.35,"timestamp":1768003687340},"delay":0,"floatShares":22979893,"shares":28997519,"eps":6.66201,"marketStatus":"休市中","change":12.5,"latestTime":"01-09 16:00:00 EST","open":254.51,"high":267.4799,"low":252.923,"amount":91119630.87759,"amplitude":0.058483,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.66201,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":248.91,"preHourTrading":{"tag":"盘前","latestPrice":254.6356,"preClose":248.91,"latestTime":"09:08 EST","volume":586,"amount":149281.90608,"timestamp":1767967706527},"postHourTrading":{"tag":"盘后","latestPrice":261.41,"preClose":261.41,"latestTime":"19:08 EST","volume":2855,"amount":746320.35,"timestamp":1768003687340},"volumeRatio":1.0880437623416195,"impliedVol":0.4458,"impliedVolPercentile":0.4422},"requestUrl":"/m/hq/s/KRYS","defaultTab":"news","newsList":[{"id":"1110133427","title":"Krystal Biotech公布KB407一期Coral-1研究积极中期临床数据，证实野生型CFTR成功递送至囊性纤维化患者肺部","url":"https://stock-news.laohu8.com/highlight/detail?id=1110133427","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110133427?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:03","pubTimestamp":1767906219,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.宣布，其KB407在一期临床试验Coral-1研究中取得积极的中期临床进展。该研究成功证实，能够将野生型CFTR递送至囊性纤维化患者的肺部。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"1177006781","title":"Krystal Biotech Inc. 报告支气管镜检查完成后24小时出现哮喘加重严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1177006781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177006781?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:03","pubTimestamp":1767906200,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc. 披露，一名患者在完成支气管镜检查24小时后，报告出现了哮喘加重的严重不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"1131298760","title":"Krystal Biotech将公布KB407治疗囊性纤维化患者1期Coral-1研究最高剂量组中期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1131298760","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131298760?lang=zh_cn&edition=full","pubTime":"2026-01-08 05:06","pubTimestamp":1767819980,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc. (KRYS) 即将发布其1期Coral-1临床试验的最新进展。此次更新重点关注最高剂量组的中期结果，该研究旨在评估基因疗法KB407对囊性纤维化患者的疗效与安全性。\n这一关键数据的披露，将为投资者和医学界提供重要参考，揭示KB407在更高剂量水平下的潜在治疗价值。公司此举标志着其在呼吸系统疾病基因治疗领域又迈出坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"1124751947","title":"Krystal Biotech 第三季度净收入为7936.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124751947","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124751947?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:27","pubTimestamp":1763569640,"startTime":"0","endTime":"0","summary":"11月3日 - Krystal Biotech 第三季度产品收入为9780万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"2582345929","title":"Krystal Biotech, Inc.涨0.77% 股价突破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2582345929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582345929?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:32","pubTimestamp":1762871528,"startTime":"0","endTime":"0","summary":"北京时间2025年11月11日22时32分，Krystal Biotech, Inc.股票出现波动，股价大幅上涨0.77%。截至发稿，该股报201.07美元/股，成交量2142股，换手率0.01%，振幅0.00%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aspire Biopharma Holdings, Inc.、Galecto, Inc.较为活跃，换手率分别为1548.92%、260.49%、111.03%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Dermata Therapeutics Inc C/Wts 、Lyell Immunopharma, Inc.，振幅分别为18.92%、12.73%、9.67%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111223208a49a17d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111223208a49a17d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS","BK4139"],"gpt_icon":0},{"id":"2581885651","title":"Krystal Biotech, Inc.涨0.17% 股价突破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581885651?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:37","pubTimestamp":1762439859,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时37分，Krystal Biotech, Inc.股票出现异动，股价快速上涨0.17%。截至发稿，该股报200.23美元/股，成交量2857股，换手率0.01%，振幅0.39%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Pharming Group Nv、Iovance Biotherapeutics, Inc.、Cytomed Therapeutics Limited涨幅较大，Osr Holdings, Inc.、Polyrizon Ltd.、Cytomed Therapeutics Limited较为活跃，换手率分别为85.39%、11.59%、7.60%，振幅较大的相关个股有Cytomed Therapeutics Limited、Osr Holdings Inc C/Wts 09/02/2028 、Cartesian Therapeutics, Inc.，振幅分别为36.49%、22.00%、15.91%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622373997586295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622373997586295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS","BK4139"],"gpt_icon":0},{"id":"1174712501","title":"Krystal Biotech Inc. 子公司在日本推出 Vyjuvek 用于治疗营养不良性大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1174712501","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174712501?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:03","pubTimestamp":1761134613,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc. 子公司在日本推出 Vyjuvek，用于治疗营养不良性大疱性表皮松解症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"1140356955","title":"Krystal Biotech Inc.获得FDA平台技术认定，其HSV-1病毒载体用于KB801治疗神经营养性角膜炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1140356955","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140356955?lang=zh_cn&edition=full","pubTime":"2025-10-14 20:04","pubTimestamp":1760443472,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.获得FDA平台技术认定，其HSV-1病毒载体用于KB801治疗神经营养性角膜炎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"gpt_icon":0},{"id":"1109283792","title":"Krystal Biotech公布肿瘤项目KB707开发计划更新，优先推进吸入式KB707治疗非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1109283792","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109283792?lang=zh_cn&edition=full","pubTime":"2025-08-22 00:12","pubTimestamp":1755792746,"startTime":"0","endTime":"0","summary":"Krystal Biotech宣布了其肿瘤治疗项目KB707开发计划的最新进展，并表示将优先开发吸入式KB707用于非小细胞肺癌的治疗。该公司对KB707项目的战略重点进行了调整，聚焦于通过吸入给药方式来治疗非小细胞肺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"2558502192","title":"Krystal Biotech, Inc.2025财年第二财季实现净利润38.33百万美元，同比增加146.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558502192","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558502192?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755291,"startTime":"0","endTime":"0","summary":"8月10日，Krystal Biotech, Inc.公布财报，公告显示公司2025财年第二财季净利润为38.33百万美元，同比增加146.18%；其中营业收入为96.04百万美元，同比增加36.65%，每股基本收益为1.33美元。从资产负债表来看，Krystal Biotech, Inc.总负债97.75百万美元，其中短期债务1.62百万美元，资产负债比为0.12，流动比率为0.10。机构评级：截至2025年8月10日，当前有11家机构对Krystal Biotech, Inc.目标价做出预测，其中目标均价为206.09美元，其中最低目标价为166.00美元，最高目标价为252.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000333a47efc51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000333a47efc51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS"],"gpt_icon":0},{"id":"2557335669","title":"美股财报 | Krystal Biotech发布Q2财报 前半年累计净利润同比增长348.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557335669","media":"同花顺iNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557335669?lang=zh_cn&edition=full","pubTime":"2025-08-05 10:00","pubTimestamp":1754359209,"startTime":"0","endTime":"0","summary":"krystal biotech发布Q2财报，2025财年前六月累计收入1.84亿美元，去年同期累计收入为1.16亿美元，同比增长59.45%。krystal biotech, Inc.于2016年4月开始运营。2017年3月，他们从加利福尼亚州有限责任公司转换为特拉华州C-corporation，并将其名称从krystal biotech, LLC更改为krystal biotech, Inc。他们在医疗保健专业人员的办公室或可能由医疗保健专业人员在患者家中制定无创或微创给药途径的载体。他们的目标是开发易于使用的药物，以显著改善患有罕见疾病和慢性疾病的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805100534a6d36f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805100534a6d36f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS"],"gpt_icon":0},{"id":"1111126611","title":"异动解读 | 克里斯特生物科技（KRYS）盈利超预期，股价却盘中大跌11.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111126611","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111126611?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:37","pubTimestamp":1754314646,"startTime":"0","endTime":"0","summary":"克里斯特生物科技公司今日盘中股价大幅下跌11.47%，尽管公司刚刚公布了超出预期的第二季度财报。根据公司发布的2025年第二季度财务报告，克里斯特生物科技的调整后每股收益达到1.29美元，显著高于分析师平均预期的1.13美元，同时也超过了去年同期的0.53美元。分析人士指出，尽管克里斯特生物科技的业绩超出预期，但市场可能对公司的未来指引或其他因素感到失望。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"gpt_icon":0},{"id":"2556387954","title":"Krystal Biotech, Inc.盘中异动 早盘股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556387954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556387954?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:31","pubTimestamp":1754314285,"startTime":"0","endTime":"0","summary":"北京时间2025年08月04日21时31分，Krystal Biotech, Inc.股票出现波动，股价快速下跌5.26%。截至发稿，该股报148.72美元/股，成交量3.2227万股，换手率0.11%，振幅3.43%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Psyence Biomedical Ltd.、Soligenix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Psyence Biomedical Ltd.、Soligenix, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为2122.12%、764.97%、379.00%，振幅较大的相关个股有凯信远达、Bioxcel Therapeutics, Inc.、Psyence Biomedical Ltd.，振幅分别为15.35%、13.50%、11.64%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080421312594cee723&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080421312594cee723&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"1148947410","title":"异动解读 | Krystal Biotech盘前大涨5.11%，二季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1148947410","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148947410?lang=zh_cn&edition=full","pubTime":"2025-08-04 20:03","pubTimestamp":1754308987,"startTime":"0","endTime":"0","summary":"基因疗法公司Krystal Biotech今日盘前大涨5.11%，主要受益于公司公布的强劲第二季度财报以及其主打产品Vyjuvek在日本市场的良好进展。分析人士指出，Krystal Biotech的业绩表现优于市场预期，特别是其产品收入的大幅增长，反映出公司在商业化方面取得了显著进展。同时，Vyjuvek在日本市场的潜在推出也为公司未来的增长前景增添了新的亮点。这些积极因素共同推动了投资者的乐观情绪，导致股价在盘前交易中大幅上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"gpt_icon":0},{"id":"2555570694","title":"Krystal Biotech, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555570694","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555570694?lang=zh_cn&edition=full","pubTime":"2025-07-29 02:53","pubTimestamp":1753728781,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日02时53分，Krystal Biotech, Inc.股票出现异动，股价急速上涨5.00%。截至发稿，该股报154.99美元/股，成交量25.8094万股，换手率0.89%，振幅4.46%。Krystal Biotech, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Celcuity Inc.、Protagenic Therapeutics Inc C/Wts 26/04/2026 、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Aim Immunotech Inc.、Tnf Pharmaceuticals, Inc.、Cervomed Inc.较为活跃，换手率分别为558.87%、322.30%、134.97%，振幅较大的相关个股有Aim Immunotech Inc.、Celcuity Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 ，振幅分别为158.93%、82.93%、75.48%。Krystal Biotech, Inc.公司简介：Krystal Biotech Inc在美国从事医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025301a4682966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729025301a4682966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KRYS"],"gpt_icon":0},{"id":"2513752603","title":"Krystal Biotech, Inc.2024财年实现净利润89.16百万美元，同比增加715.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513752603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513752603?lang=zh_cn&edition=full","pubTime":"2025-02-24 03:00","pubTimestamp":1740337251,"startTime":"0","endTime":"0","summary":"2月24日，Krystal Biotech, Inc.公布财报，公告显示公司2024财年净利润为89.16百万美元，同比增加715.74%；其中营业收入为2.91亿美元，同比增加473.96%，每股基本收益为3.12美元。从资产负债表来看，Krystal Biotech, Inc.总负债1.09亿美元，其中短期债务1.22百万美元，资产负债比为9.69，流动比率为7.28。机构评级：截至2025年2月24日，当前有9家机构对Krystal Biotech, Inc.目标价做出预测，其中目标均价为211.44美元，其中最低目标价为195.00美元，最高目标价为221.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS"],"gpt_icon":0},{"id":"1157840734","title":"异动解读 | 基因疗法公司研发利好 Krystal Biotech Inc.盘中大涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157840734","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157840734?lang=zh_cn&edition=full","pubTime":"2025-02-20 23:00","pubTimestamp":1740063626,"startTime":"0","endTime":"0","summary":"生物科技公司Krystal Biotech Inc.(KRYS)今日盘中大涨5.61%,引发市场广泛关注。\n\n据分析,这主要得益于分析师机构Chardan Capital发布研究报告,维持该公司股票评级为\"买入\",并将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech Inc.是一家专注于开发新型生物疫苗和基因疗法的临床阶段公司。公司最近在研发方面取得了一定进展,这增强了市场对其长期增长潜力的信心,成为分析师上调评级目标价的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"gpt_icon":0},{"id":"1124658988","title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1124658988","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124658988?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:28","pubTimestamp":1740061707,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(KRYS)今日盘前大涨5.02%,引发市场关注。\n\n分析师机构Chardan Capital发布研报,维持该公司股票评级为\"买入\",同时将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech是一家临床阶段的基因疗法公司,专注于开发新型生物疫苗。公司最近取得了一些研发进展,这可能是分析师上调评级目标价的主要原因。总体来说,市场对该公司长期增长潜力充满信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"gpt_icon":0},{"id":"2512448404","title":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512448404","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512448404?lang=zh_cn&edition=full","pubTime":"2025-02-20 19:10","pubTimestamp":1740049835,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20191048285027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KRYS"],"gpt_icon":0},{"id":"1178376665","title":"异动解读 | Krystal Biotech财报超预期 股价暴涨5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178376665","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178376665?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:39","pubTimestamp":1739975979,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(纳斯达克代码:KRYS)盘中股价大涨5.85%,引起了资本市场的关注。\n\n导致该股暴涨的主因是Krystal Biotech公布了2024年第四季度财报,实现了业绩超预期。\n\n具体来看,Krystal Biotech2024年第四季度实现每股收益1.52美元,较去年同期快速增长406.67%,并高于分析师普遍预期31.03%。销售额达到91.14百万美元,同比增长116.26%,超出分析师预期0.72%。公司业绩显著增长,销售额和利润率均超过市场预期,让投资者对公司长期发展前景更加看好,从而推动了当日股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.krystalbio.com","stockEarnings":[{"period":"1week","weight":0.0587},{"period":"1month","weight":0.0905},{"period":"3month","weight":0.4405},{"period":"6month","weight":0.7643},{"period":"1year","weight":0.6685},{"period":"ytd","weight":0.0603}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Krystal Biotech, Inc.于2016年4月开始运营。2017年3月，他们从加利福尼亚州有限责任公司转换为特拉华州C-corporation，并将其名称从Krystal Biotech, LLC更改为Krystal Biotech, Inc。该公司是一家专注于为罕见病患者开发和商业化基因药物的生物技术公司。利用他们基于工程化HSV-1的专利平台，他们创造了载体，可以有效地将治疗性转基因传递给多器官系统中感兴趣的细胞。然后，细胞自身的机制转录并翻译编码的效应物来治疗或预防疾病。他们在医疗保健专业人员的办公室或可能由医疗保健专业人员在患者家中制定无创或微创给药途径的载体。他们的目标是开发易于使用的药物，以显著改善患有罕见疾病和慢性疾病的患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.004002},{"month":2,"riseRate":0.75,"avgChangeRate":0.093738},{"month":3,"riseRate":0.625,"avgChangeRate":0.050497},{"month":4,"riseRate":0.375,"avgChangeRate":-0.020845},{"month":5,"riseRate":0.5,"avgChangeRate":0.012748},{"month":6,"riseRate":0.75,"avgChangeRate":0.115596},{"month":7,"riseRate":0.75,"avgChangeRate":0.07679},{"month":8,"riseRate":0.125,"avgChangeRate":-0.010983},{"month":9,"riseRate":0.25,"avgChangeRate":-0.037914},{"month":10,"riseRate":0.555556,"avgChangeRate":0.053086},{"month":11,"riseRate":0.888889,"avgChangeRate":0.190014},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.011676}],"exchange":"NASDAQ","name":"Krystal Biotech Inc.","nameEN":"Krystal Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Krystal Biotech Inc.,KRYS,Krystal Biotech Inc.股票,Krystal Biotech Inc.股票老虎,Krystal Biotech Inc.股票老虎国际,Krystal Biotech Inc.行情,Krystal Biotech Inc.股票行情,Krystal Biotech Inc.股价,Krystal Biotech Inc.股市,Krystal Biotech Inc.股票价格,Krystal Biotech Inc.股票交易,Krystal Biotech Inc.股票购买,Krystal Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}